DOI: 10.36347/sjmcr.2020.v08i04.022

Pages: 496-498

Gastric cancer is one of the most common cancers worldwide. Its most common histological form is adenocarcinoma. Perioperative chemotherapy is currently the reference treatment for resectable gastric adenocarcinomas, yet the surgery is the only potentially curative treatment. We report the case of a 50 year old patient, with a history of diabetes, hospitalized for epicastric pain evolving for several months in a context of unencrypted weight loss. The eso-gastric endoscopy revealed a large ulcero-proliferative growth in the antro-pyloric region while the anatomopathological study of the biopsy revealed an undifferentiated carcinomatous gastric process. The CT scan finds a locally advanced gastric antropyloric tumor. The patient received perioperative FLOT protocol chemotherapy with an excellent therapeutic response which has been demonstrated on the CT scan that has shown the absence of any gastric thickening or pancreatic processes. A distal subtotal gastrectomy was performed, with modified D2 (D1+) lymphadenectomy and a Billroth II Reconstruction. The anatomopathological study of the surgical piece revealed the absence of dysplasia or tumor proliferation. Postoperative recovery was uneventful and the patient received postoperative chemotherapy with a favorable evolution to date. Gastric cancer is a common tumor that requires multidisciplinary care for optimal therapeutic strategy. Perioperative chemotherapy is the reference treatment for resectable gastric adenocarcinomas; it allows the evaluation of chemical response, to have a downstaging that may facilitate surgery while getting an early systemic effect.